“List of Occupational Diseases” Annexed to the List of Occupational Diseases Recommendation, 2002 (No
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
EFFECTIVE NEBRASKA DEPARTMENT of 01/01/2017 HEALTH and HUMAN SERVICES 173 NAC 1 I TITLE 173 COMMUNICABLE DISEASES CHAPTER 1
EFFECTIVE NEBRASKA DEPARTMENT OF 01/01/2017 HEALTH AND HUMAN SERVICES 173 NAC 1 TITLE 173 COMMUNICABLE DISEASES CHAPTER 1 REPORTING AND CONTROL OF COMMUNICABLE DISEASES TABLE OF CONTENTS SECTION SUBJECT PAGE 1-001 SCOPE AND AUTHORITY 1 1-002 DEFINITIONS 1 1-003 WHO MUST REPORT 2 1-003.01 Healthcare Providers (Physicians and Hospitals) 2 1-003.01A Reporting by PA’s and APRN’s 2 1-003.01B Reporting by Laboratories in lieu of Physicians 3 1-003.01C Reporting by Healthcare Facilities in lieu of Physicians for 3 Healthcare Associated Infections (HAIs) 1-003.02 Laboratories 3 1-003.02A Electronic Ordering of Laboratory Tests 3 1-004 REPORTABLE DISEASES, POISONINGS, AND ORGANISMS: 3 LISTS AND FREQUENCY OF REPORTS 1-004.01 Immediate Reports 4 1-004.01A List of Diseases, Poisonings, and Organisms 4 1-004.01B Clusters, Outbreaks, or Unusual Events, Including Possible 5 Bioterroristic Attacks 1-004.02 Reports Within Seven Days – List of Reportable Diseases, 5 Poisonings, and Organisms 1-004.03 Reporting of Antimicrobial Susceptibility 8 1-004.04 New or Emerging Diseases and Other Syndromes and Exposures – 8 Reporting and Submissions 1-004.04A Criteria 8 1-004.04B Surveillance Mechanism 8 1-004.05 Sexually Transmitted Diseases 9 1-004.06 Healthcare Associated Infections 9 1-005 METHODS OF REPORTING 9 1-005.01 Health Care Providers 9 1-005.01A Immediate Reports of Diseases, Poisonings, and Organisms 9 1-005.01B Immediate Reports of Clusters, Outbreaks, or Unusual Events, 9 Including Possible Bioterroristic Attacks i EFFECTIVE NEBRASKA DEPARTMENT OF -
DIAGNOSIS and TREATMENT of BRUCELLOSIS (Undulant Fever)
DIAGNOSIS AND TREATMENT OF BRUCELLOSIS (Undulant Fever) CHARLES L. HARTSOCK, M.D. Not only the treatment but also the diagnosis of undulant fever are far from being satisfactory, although many types of therapy are being tried and critically evaluated. Because of the tremendous scope of the disease, frequent discussions and reappraisals of our ideas about bru- cellosis will be absolutely essential for some time. Some physicians more or less disregard brucellosis and even scoff at the chronic phase of this new intruder in the realm of human disease. Others are overenthusi- astic and attempt to explain many vague and indefinite problems upon the basis of chronic brucellosis without sufficient evidence. Still other physicians have lost their original enthusiasm and have reverted to the first viewpoint, probably because of the great difficulty in coping with the caprices and vagaries of this disease and the marked uncertainties in diagnosis and treatment. Even though this disease is extremely protean and remarkably bizarre in its manifestations, it is a disease of known causative organism to which the generic term of brucella has been given. The original infection in man was traced to the drinking of goat's milk on the Island of Malta, and for many years this disease was known as Malta fever. Because of the undulating character of the fever with a tendency for remissions and recurrences, it was later called undulant fever which proved to be a very poor description of the febrile reaction in many instances. Brucellosis is the more specific term derived from the organism causing the disease. Three strains of the brucella organism have been isolated and named for their respective hosts: b. -
A Retrospective Chart Review Examining the Clinical Utility of Family Health History
Sarah Lawrence College DigitalCommons@SarahLawrence The Joan H. Marks Graduate Program in Human Genetics Theses Human Genetics 5-2017 A Retrospective Chart Review Examining the Clinical Utility of Family Health History Katherine Dao Sarah Lawrence College Julia Russo Sarah Lawrence College Follow this and additional works at: https://digitalcommons.slc.edu/genetics_etd Part of the Genetics Commons Recommended Citation Dao, Katherine and Russo, Julia, "A Retrospective Chart Review Examining the Clinical Utility of Family Health History" (2017). Human Genetics Theses. 33. https://digitalcommons.slc.edu/genetics_etd/33 This Thesis - Open Access is brought to you for free and open access by the The Joan H. Marks Graduate Program in Human Genetics at DigitalCommons@SarahLawrence. It has been accepted for inclusion in Human Genetics Theses by an authorized administrator of DigitalCommons@SarahLawrence. For more information, please contact [email protected]. Katherine Dao and Julia Russo A Retrospective Chart Review Examining the Clinical Utility of Family Health History Authors: Katherine Dao, Julia Russo, Jennifer L. Garbarini, Sheila C. Johal, Shannon Wieloch Submitted in partial completion of the Master of Science Degree at Sarah Lawrence College, May 2017 1/34 Katherine Dao and Julia Russo Abstract Family health history (FHH) is a simple and cost-effective clinical tool widely used by genetic professionals. Although the value of FHH for assessing personal and familial health and reproductive risk within a prenatal population has been demonstrated in past studies, its utility within a genetic carrier screening population has not been evaluated. The purpose of this study was to examine the utility of FHH as a clinical screening tool and explore the general outcomes of full FHH evaluations within an expanded carrier screening (ECS) population. -
European Conference on Rare Diseases
EUROPEAN CONFERENCE ON RARE DISEASES Luxembourg 21-22 June 2005 EUROPEAN CONFERENCE ON RARE DISEASES Copyright 2005 © Eurordis For more information: www.eurordis.org Webcast of the conference and abstracts: www.rare-luxembourg2005.org TABLE OF CONTENT_3 ------------------------------------------------- ACKNOWLEDGEMENTS AND CREDITS A specialised clinic for Rare Diseases : the RD TABLE OF CONTENTS Outpatient’s Clinic (RDOC) in Italy …………… 48 ------------------------------------------------- ------------------------------------------------- 4 / RARE, BUT EXISTING The organisers particularly wish to thank ACKNOWLEDGEMENTS AND CREDITS 4.1 No code, no name, no existence …………… 49 ------------------------------------------------- the following persons/organisations/companies 4.2 Why do we need to code rare diseases? … 50 PROGRAMME COMMITTEE for their role : ------------------------------------------------- Members of the Programme Committee ……… 6 5 / RESEARCH AND CARE Conference Programme …………………………… 7 …… HER ROYAL HIGHNESS THE GRAND DUCHESS OF LUXEMBOURG Key features of the conference …………………… 12 5.1 Research for Rare Diseases in the EU 54 • Participants ……………………………………… 12 5.2 Fighting the fragmentation of research …… 55 A multi-disciplinary approach ………………… 55 THE EUROPEAN COMMISSION Funding of the conference ……………………… 14 Transfer of academic research towards • ------------------------------------------------- industrial development ………………………… 60 THE GOVERNEMENT OF LUXEMBOURG Speakers ……………………………………………… 16 Strengthening cooperation between academia -
Diseases Transmitted Through the Food Supply
DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Diseases Transmitted through the Food Supply AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Notice of annual update of list of infectious and communicable diseases that are transmitted through handling the food supply and the methods by which such diseases are transmitted. SUMMARY: Section 103 (d) of the Americans with Disabilities Act of 1990, Public Law 101–336, requires the Secretary to publish a list of infectious and communicable diseases that are transmitted through handling the food supply and to review and update the list annually. The Centers for Disease Control and Prevention (CDC) published a final list on August 16, 1991 (56 FR40897) and updates on September 8, 1992 (57 FR 40917); January 13, 1994 (59 FR 1949); August 15, 1996 (61 FR 42426); September 22, 1997 (62 FR 49518–9); September 15, 1998 (63 FR 49359); September 21, 1999 (64 FR 51127); September 27, 2000 (65 FR 58088); September 10, 2001 (66 FR 47030); September 27, 2002 (67 FR 61109); September 26, 2006 (71 FR 56152); November 17, 2008 (73 FR 67871); and November 29, 2009 (74 FR 61151). The final list has been reviewed in light of new information and has been revised as set forth below. DATES: Effective Date: January 31, 2014. FOR FURTHER INFORMATION CONTACT: Dr. Art Liang, Division of Foodborne Waterborne and Environment Diseases, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention (CDC), 1600 Clifton Road, NE., Mailstop G–24, Atlanta, Georgia 30333. -
ICD-10 International Statistical Classification of Diseases and Related Health Problems
ICD-10 International Statistical Classification of Diseases and Related Health Problems 10th Revision Volume 2 Instruction manual 2010 Edition WHO Library Cataloguing-in-Publication Data International statistical classification of diseases and related health problems. - 10th revision, edition 2010. 3 v. Contents: v. 1. Tabular list – v. 2. Instruction manual – v. 3. Alphabetical index. 1.Diseases - classification. 2.Classification. 3.Manuals. I.World Health Organization. II.ICD-10. ISBN 978 92 4 154834 2 (NLM classification: WB 15) © World Health Organization 2011 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. -
FAQ REGARDING DISEASE REPORTING in MONTANA | Rev
Disease Reporting in Montana: Frequently Asked Questions Title 50 Section 1-202 of the Montana Code Annotated (MCA) outlines the general powers and duties of the Montana Department of Public Health & Human Services (DPHHS). The three primary duties that serve as the foundation for disease reporting in Montana state that DPHHS shall: • Study conditions affecting the citizens of the state by making use of birth, death, and sickness records; • Make investigations, disseminate information, and make recommendations for control of diseases and improvement of public health to persons, groups, or the public; and • Adopt and enforce rules regarding the reporting and control of communicable diseases. In order to meet these obligations, DPHHS works closely with local health jurisdictions to collect and analyze disease reports. Although anyone may report a case of communicable disease, such reports are submitted primarily by health care providers and laboratories. The Administrative Rules of Montana (ARM), Title 37, Chapter 114, Communicable Disease Control, outline the rules for communicable disease control, including disease reporting. Communicable disease surveillance is defined as the ongoing collection, analysis, interpretation, and dissemination of disease data. Accurate and timely disease reporting is the foundation of an effective surveillance program, which is key to applying effective public health interventions to mitigate the impact of disease. What diseases are reportable? A list of reportable diseases is maintained in ARM 37.114.203. The list continues to evolve and is consistent with the Council of State and Territorial Epidemiologists (CSTE) list of Nationally Notifiable Diseases maintained by the Centers for Disease Control and Prevention (CDC). In addition to the named conditions on the list, any occurrence of a case/cases of communicable disease in the 20th edition of the Control of Communicable Diseases Manual with a frequency in excess of normal expectancy or any unusual incident of unexplained illness or death in a human or animal should be reported. -
Optional Ashkenazi Panel Brochure
בס’’ד Fulfilling Our Responsibility To The Next Generation A VITAL PROGRAM THAT SAVES LIVES! The Dor Yeshorim mission: For over 30 years, Dor Yeshorim has successfully prevented the occurrence of genetic diseases in our NOW AVAILABLE: families. Since 1983, Dor Yeshorim with Hashem’s help NEW PANEL OF TESTS has successfully prevented genetic diseases from affecting our Jewish Community by conducting mass screenings in high schools, colleges, universities, FOR SEVEN ADDITIONAL yeshivas and seminaries worldwide- throughout the United States, Israel, Canada, Europe, and countless other orthodox Jewish communities. DEVASTATING AND The Dor Yeshorim genetic screening program was established to provide protection from Jewish genetic diseases, while safeguarding individuals from the potentiallY FatAL psychological stigma associated with knowing their carrier status. DISEASES To date, approximately 375,000 individual genetic screening tests have been performed, and nearly 2,000 potential couples have been spared the List of Diseases: agony of giving birth to a child or children with a 1. Bardet–Biedl Syndrome Type 2 (BBS2) devastating or fatal genetic disease. The birth of a sick child not only impacts the parents of this child 2. Nemaline Myopathy (NM) but also the siblings, grandpare nts and the extended 3. Dihyrolipoamide Dehydrogenase Deficiency (DLDD) family. B’H Dor Yeshorim has been able to spare over 4. Usher Syndrome Type 1 (USH1) 2,000 families the hardships associated with having such a child. 5. Joubert Syndrome (JBTS) DY benefits from -
ICD-10 International Statistical Classification of Diseases And
ICD-10 International statistical classification of diseases and related health problems 10th revision Volume 2 Instruction manual Fifth edition 2016 Volume 2.indb 1 11/09/15 10:46 WHO Library Cataloguing-in-Publication Data International statistical classification of diseases and related health problems. - 10th revision, Fifth edition, 2016. 3 v. Contents: v. 1. Tabular list -- v. 2. Instruction manual -- v. 3. Alphabetical index. 1.Diseases - classification. 2.Classification. 3.Manuals. I.World Health Organization. II.ICD-10. ISBN 978 92 4 154916 5 (NLM classification: WB 15) © World Health Organization 2011. Reprinted in 2015. All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. -
The Blemishes of Modern Society? Acne Prevalence in the Dogon of Mali Christine E
325 original Evolution, Medicine, and Public Health [2016] pp. 325–337 research doi:10.1093/emph/eow027 article The blemishes of modern society? Acne prevalence in the Dogon of Mali Christine E. Campbell1 and Beverly I. Strassmann*,1 1Department of Anthropology & Institute for Social Research, University of Michigan, Ann Arbor, MI, USA *Corresponding author. Department of Anthropology & Research Center for Group Dynamics, University of Michigan, 426 Thompson St, Ann Arbor, MI 48104, USA. E-mail: [email protected] Received 26 May 2016; revised version accepted 00 0000 ABSTRACT Background and Objectives: Non-communicable diseases may reflect an evolutionary mismatch be- tween our human ancestry and modern environments. To explore the mismatch hypothesis for Acne vulgaris, we studied the prevalence and severity of acne in Dogon adolescents in Mali, West Africa. Methodology: We graded the prevalence and severity of acne in 1182 Dogon adolescents aged 11–18 years from nine villages using facial photos taken as part of a prospective cohort study. Eighty-nine (89%) of the individuals in the cohort migrated to the city during adolescence, enabling us to assess the effect of urban migration. Using multivariable logistic regression, we estimated the effect of predictor variables on the presence of acne. Results: The prevalence of acne in the cohort was 28%, with 90% of cases being mild or very mild. Thus, the prevalence and severity of acne was much lower than for adolescents in high-income countries. Controlling for age, puberty, and body mass index (BMI), the odds of boys developing acne was 85% lower in the city than in the villages (P = 0.002). -
Summary of Notifiable Diseases — United States, 2010
Morbidity and Mortality Weekly Report Weekly / Vol. 59 / No. 53 June 1, 2012 Summary of Notifiable Diseases — United States, 2010 U.S. Department of Health and Human Services Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report CONTENTS Preface .......................................................................................................................2 TABLE 5. Reported cases and incidence* of notifiable diseases,† by Background .............................................................................................................2 race — United States, 2010 .......................................................................... 43 Infectious Diseases Designated as Notifiable at the National Level TABLE 6. Reported cases and incidence* of notifiable diseases,† by during 2010* .........................................................................................................3 ethnicity — United States, 2010 ................................................................. 45 Data Sources ...........................................................................................................4 PART 2: Graphs and Maps for Selected Notifiable Diseases Interpreting Data ...................................................................................................4 in the United States, 2010 ............................................................................. 47 Transition in NNDSS Data Collection and Reporting ................................5 PART 3: Historical Summaries -
Prioritizing Zoonotic Diseases for Multisectoral, One Health Collaboration in the United States Workshop Summary
Prioritizing Zoonotic Diseases for Multisectoral, One Health Collaboration in the United States Workshop Summary CS29887A ONE HEALTH ZOONOTIC DISEASE PRIORITIZATION WORKSHOP REPORT, UNITED STATES Photo 1. A brown bear in the forest. ii ONE HEALTH ZOONOTIC DISEASE PRIORITIZATION WORKSHOP REPORT, UNITED STATES TABLE OF CONTENTS Participating Organizations ........................................................................................................................................................... iv Executive Summary ............................................................................................................................................................................. 1 Background ............................................................................................................................................................................................ 21 Workshop Methods ....................................................................................................................................................................... 30 Recommendations for Next Steps ........................................................................................................................................... 35 APPENDIX A: Overview of the One Health Zoonotic Disease Prioritization Process ................................ 39 APPENDIX B: One Health Zoonotic Disease Prioritization Workshop Participants for the United States ...............................................................................................................................................................................